APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

NMDA Receptor Antagonist

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global NMDA Receptor Antagonist Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 174017400330 December 2025199 pages

Choose your research edition.

Industry ResearchNMDA Receptor Antagonist Industry Research Report 2026126 pages · $2,950 USDIndustry Growth & TrendsGlobal NMDA Receptor Antagonist Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal NMDA Receptor Antagonist Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal NMDA Receptor Antagonist Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal NMDA Receptor Antagonist Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global NMDA Receptor Antagonist market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for NMDA Receptor Antagonist is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for NMDA Receptor Antagonist is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for NMDA Receptor Antagonist is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for NMDA Receptor Antagonist is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of NMDA Receptor Antagonist include Algernon Pharmaceuticals, ATAI Life Sciences, Avanir Pharmaceuticals, Axsome Therapeutics, Bexson Biomedical, Cessatech, DemeRx, PharmaTher and Relmada Therapeutics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global NMDA Receptor Antagonist market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of NMDA Receptor Antagonist and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents NMDA Receptor Antagonist sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the NMDA Receptor Antagonist market size, projected growth trends, production technologies, key applications, and end-use industries.

NMDA Receptor Antagonist Segment by Company

Algernon Pharmaceuticals

ATAI Life Sciences

Avanir Pharmaceuticals

Axsome Therapeutics

Bexson Biomedical

Cessatech

DemeRx

PharmaTher

Relmada Therapeutics

Seelos Therapeutics

Small Pharma

UCB

NMDA Receptor Antagonist Segment by Type

Vaccine

Monoclonal Antibody

NMDA Receptor Antagonist Segment by Application

Parkinson's Disease

Alzheimer's Disease

Others

NMDA Receptor Antagonist Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global NMDA Receptor Antagonist market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of NMDA Receptor Antagonist and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of NMDA Receptor Antagonist.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the NMDA Receptor Antagonist market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of NMDA Receptor Antagonist manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of NMDA Receptor Antagonist in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of NMDA Receptor Antagonist in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. NMDA Receptor Antagonist Industry Trends Table 2. NMDA Receptor Antagonist Industry Drivers Table 3. NMDA Receptor Antagonist Industry Opportunities and Challenges Table 4. NMDA Receptor Antagonist Industry Restraints Table 5. Global NMDA Receptor Antagonist Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global NMDA Receptor Antagonist Revenue Market Share by Manufacturers (2021-2026) Table 7. Global NMDA Receptor Antagonist Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global NMDA Receptor Antagonist Sales Market Share by Manufacturers Table 9. Global NMDA Receptor Antagonist Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global NMDA Receptor Antagonist Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global NMDA Receptor Antagonist Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global NMDA Receptor Antagonist Manufacturers, Product Type & Application Table 13. Global NMDA Receptor Antagonist Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global NMDA Receptor Antagonist by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Vaccine Table 17. Major Manufacturers of Monoclonal Antibody Table 18. Global NMDA Receptor Antagonist Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 19. Global NMDA Receptor Antagonist Sales by Type (2021-2026) & (K Units) Table 20. Global NMDA Receptor Antagonist Sales by Type (2027-2032) & (K Units) Table 21. Global NMDA Receptor Antagonist Sales Market Share by Type (2021-2026) Table 22. Global NMDA Receptor Antagonist Sales Market Share by Type (2027-2032) Table 23. Global NMDA Receptor Antagonist Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global NMDA Receptor Antagonist Revenue by Type (2021-2026) & (K Units) Table 25. Global NMDA Receptor Antagonist Revenue by Type (2027-2032) & (K Units) Table 26. Global NMDA Receptor Antagonist Revenue Market Share by Type (2021-2026) Table 27. Global NMDA Receptor Antagonist Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Parkinson's Disease Table 29. Major Manufacturers of Alzheimer's Disease Table 30. Major Manufacturers of Others Table 31. Global NMDA Receptor Antagonist Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 32. Global NMDA Receptor Antagonist Sales by Application (2021-2026) & (K Units) Table 33. Global NMDA Receptor Antagonist Sales by Application (2027-2032) & (K Units) Table 34. Global NMDA Receptor Antagonist Sales Market Share by Application (2021-2026) Table 35. Global NMDA Receptor Antagonist Sales Market Share by Application (2027-2032) Table 36. Global NMDA Receptor Antagonist Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global NMDA Receptor Antagonist Revenue by Application (2021-2026) & (K Units) Table 38. Global NMDA Receptor Antagonist Revenue by Application (2027-2032) & (K Units) Table 39. Global NMDA Receptor Antagonist Revenue Market Share by Application (2021-2026) Table 40. Global NMDA Receptor Antagonist Revenue Market Share by Application (2027-2032) Table 41. Global NMDA Receptor Antagonist Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 42. Global NMDA Receptor Antagonist Sales by Region (2021-2026) & (K Units) Table 43. Global NMDA Receptor Antagonist Sales Market Share by Region (2021-2026) Table 44. Global NMDA Receptor Antagonist Sales Forecasted by Region (2027-2032) & (K Units) Table 45. Global NMDA Receptor Antagonist Sales Forecasted Market Share by Region (2027-2032) Table 46. North America NMDA Receptor Antagonist Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 47. North America NMDA Receptor Antagonist Sales by Country (2021-2026) & (K Units) Table 48. North America NMDA Receptor Antagonist Sales by Country (2027-2032) & (K Units) Table 49. Europe NMDA Receptor Antagonist Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. Europe NMDA Receptor Antagonist Sales by Country (2021-2026) & (K Units) Table 51. Europe NMDA Receptor Antagonist Sales by Country (2027-2032) & (K Units) Table 52. Asia Pacific NMDA Receptor Antagonist Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Asia Pacific NMDA Receptor Antagonist Sales by Country (2021-2026) & (K Units) Table 54. Asia Pacific NMDA Receptor Antagonist Sales by Country (2027-2032) & (K Units) Table 55. South America, Middle East and Africa NMDA Receptor Antagonist Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. South America, Middle East and Africa NMDA Receptor Antagonist Sales by Country (2021-2026) & (K Units) Table 57. South America, Middle East and Africa NMDA Receptor Antagonist Sales by Country (2027-2032) & (K Units) Table 58. Global NMDA Receptor Antagonist Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global NMDA Receptor Antagonist Revenue by Region (2021-2026) & (US$ Million) Table 60. Global NMDA Receptor Antagonist Revenue by Region (2027-2032) & (US$ Million) Table 61. Global NMDA Receptor Antagonist Revenue Market Share by Region (2021-2026) Table 62. Global NMDA Receptor Antagonist Revenue Market Share by Region (2027-2032) Table 63. Algernon Pharmaceuticals Company Information Table 64. Algernon Pharmaceuticals Business Overview Table 65. Algernon Pharmaceuticals NMDA Receptor Antagonist Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Algernon Pharmaceuticals NMDA Receptor Antagonist Product Portfolio Table 67. Algernon Pharmaceuticals Recent Development Table 68. ATAI Life Sciences Company Information Table 69. ATAI Life Sciences Business Overview Table 70. ATAI Life Sciences NMDA Receptor Antagonist Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. ATAI Life Sciences NMDA Receptor Antagonist Product Portfolio Table 72. ATAI Life Sciences Recent Development Table 73. Avanir Pharmaceuticals Company Information Table 74. Avanir Pharmaceuticals Business Overview Table 75. Avanir Pharmaceuticals NMDA Receptor Antagonist Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Avanir Pharmaceuticals NMDA Receptor Antagonist Product Portfolio Table 77. Avanir Pharmaceuticals Recent Development Table 78. Axsome Therapeutics Company Information Table 79. Axsome Therapeutics Business Overview Table 80. Axsome Therapeutics NMDA Receptor Antagonist Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Axsome Therapeutics NMDA Receptor Antagonist Product Portfolio Table 82. Axsome Therapeutics Recent Development Table 83. Bexson Biomedical Company Information Table 84. Bexson Biomedical Business Overview Table 85. Bexson Biomedical NMDA Receptor Antagonist Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Bexson Biomedical NMDA Receptor Antagonist Product Portfolio Table 87. Bexson Biomedical Recent Development Table 88. Cessatech Company Information Table 89. Cessatech Business Overview Table 90. Cessatech NMDA Receptor Antagonist Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Cessatech NMDA Receptor Antagonist Product Portfolio Table 92. Cessatech Recent Development Table 93. DemeRx Company Information Table 94. DemeRx Business Overview Table 95. DemeRx NMDA Receptor Antagonist Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. DemeRx NMDA Receptor Antagonist Product Portfolio Table 97. DemeRx Recent Development Table 98. PharmaTher Company Information Table 99. PharmaTher Business Overview Table 100. PharmaTher NMDA Receptor Antagonist Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. PharmaTher NMDA Receptor Antagonist Product Portfolio Table 102. PharmaTher Recent Development Table 103. Relmada Therapeutics Company Information Table 104. Relmada Therapeutics Business Overview Table 105. Relmada Therapeutics NMDA Receptor Antagonist Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. Relmada Therapeutics NMDA Receptor Antagonist Product Portfolio Table 107. Relmada Therapeutics Recent Development Table 108. Seelos Therapeutics Company Information Table 109. Seelos Therapeutics Business Overview Table 110. Seelos Therapeutics NMDA Receptor Antagonist Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 111. Seelos Therapeutics NMDA Receptor Antagonist Product Portfolio Table 112. Seelos Therapeutics Recent Development Table 113. Small Pharma Company Information Table 114. Small Pharma Business Overview Table 115. Small Pharma NMDA Receptor Antagonist Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 116. Small Pharma NMDA Receptor Antagonist Product Portfolio Table 117. Small Pharma Recent Development Table 118. UCB Company Information Table 119. UCB Business Overview Table 120. UCB NMDA Receptor Antagonist Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 121. UCB NMDA Receptor Antagonist Product Portfolio Table 122. UCB Recent Development Table 123. Key Raw Materials Table 124. Raw Materials Key Suppliers Table 125. NMDA Receptor Antagonist Distributors List Table 126. NMDA Receptor Antagonist Customers List Table 127. Research Programs/Design for This Report Table 128. Authors List of This Report Table 129. Secondary Sources Table 130. Primary Sources List of Figures Figure 1. NMDA Receptor Antagonist Product Image Figure 2. Global NMDA Receptor Antagonist Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global NMDA Receptor Antagonist Market Size (2021-2032) & (US$ Million) Figure 4. Global NMDA Receptor Antagonist Sales (2021-2032) & (K Units) Figure 5. Global NMDA Receptor Antagonist Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 NMDA Receptor Antagonist Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Vaccine Image Figure 9. Monoclonal Antibody Image Figure 10. Global NMDA Receptor Antagonist Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 11. Global NMDA Receptor Antagonist Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global NMDA Receptor Antagonist Sales Market Share by Type (2021-2032) Figure 13. Global NMDA Receptor Antagonist Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global NMDA Receptor Antagonist Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global NMDA Receptor Antagonist Revenue Market Share by Type (2021-2032) Figure 16. Parkinson's Disease Image Figure 17. Alzheimer's Disease Image Figure 18. Others Image Figure 19. Global NMDA Receptor Antagonist Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 20. Global NMDA Receptor Antagonist Sales Market Share 2021 VS 2025 VS 2032 Figure 21. Global NMDA Receptor Antagonist Sales Market Share by Application (2021-2032) Figure 22. Global NMDA Receptor Antagonist Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global NMDA Receptor Antagonist Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global NMDA Receptor Antagonist Revenue Market Share by Application (2021-2032) Figure 25. North America NMDA Receptor Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 26. North America NMDA Receptor Antagonist Sales Market Share by Country (2021-2032) Figure 27. U.S. NMDA Receptor Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 28. Canada NMDA Receptor Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Mexico NMDA Receptor Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Europe NMDA Receptor Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Europe NMDA Receptor Antagonist Sales Market Share by Country (2021-2032) Figure 32. Germany NMDA Receptor Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 33. France NMDA Receptor Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 34. U.K. NMDA Receptor Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Italy NMDA Receptor Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Netherlands NMDA Receptor Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Asia Pacific NMDA Receptor Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Asia Pacific NMDA Receptor Antagonist Sales Market Share by Country (2021-2032) Figure 39. China NMDA Receptor Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Japan NMDA Receptor Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 41. South Korea NMDA Receptor Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Southeast Asia NMDA Receptor Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 43. India NMDA Receptor Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Australia NMDA Receptor Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 45. South America, Middle East and Africa NMDA Receptor Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South America, Middle East and Africa NMDA Receptor Antagonist Sales Market Share by Country (2021-2032) Figure 47. Brazil NMDA Receptor Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South Africa NMDA Receptor Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Saudi Arabia NMDA Receptor Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Turkey NMDA Receptor Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Argentina NMDA Receptor Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 52. UAE NMDA Receptor Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Egypt NMDA Receptor Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Chile NMDA Receptor Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Global NMDA Receptor Antagonist Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Global NMDA Receptor Antagonist Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 57. North America NMDA Receptor Antagonist Revenue (2021-2032) & (US$ Million) Figure 58. North America NMDA Receptor Antagonist Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe NMDA Receptor Antagonist Revenue (2021-2032) & (US$ Million) Figure 60. Europe NMDA Receptor Antagonist Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific NMDA Receptor Antagonist Revenue (2021-2032) & (US$ Million) Figure 62. Asia-Pacific NMDA Receptor Antagonist Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. South America, Middle East and Africa NMDA Receptor Antagonist Revenue (2021-2032) & (US$ Million) Figure 64. South America, Middle East and Africa NMDA Receptor Antagonist Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. NMDA Receptor Antagonist Value Chain Figure 66. Manufacturing Cost Structure Figure 67. NMDA Receptor Antagonist Production Mode & Process Figure 68. Direct Comparison with Distribution Share Figure 69. Distributors Profiles Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Vaccine
  • Monoclonal Antibody
Applications
  • Parkinson's Disease
  • Alzheimer's Disease
  • Others
Companies covered
  • Algernon Pharmaceuticals
  • ATAI Life Sciences
  • Avanir Pharmaceuticals
  • Axsome Therapeutics
  • Bexson Biomedical
  • Cessatech
  • DemeRx
  • PharmaTher
  • Relmada Therapeutics
  • Seelos Therapeutics
  • Small Pharma
  • UCB

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global NMDA Receptor Antagonist Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global NMDA Receptor Antagonist Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global NMDA Receptor Antagonist Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global NMDA Receptor Antagonist Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global NMDA Receptor Antagonist Market Dynamics
  1. 2.1 NMDA Receptor Antagonist Industry Trends
  2. 2.2 NMDA Receptor Antagonist Industry Drivers
  3. 2.3 NMDA Receptor Antagonist Industry Opportunities and Challenges
  4. 2.4 NMDA Receptor Antagonist Industry Restraints
3 NMDA Receptor Antagonist Market by Manufacturers
  1. 3.1 Global NMDA Receptor Antagonist Revenue by Manufacturers (2021-2026)
  2. 3.2 Global NMDA Receptor Antagonist Sales by Manufacturers (2021-2026)
  3. 3.3 Global NMDA Receptor Antagonist Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global NMDA Receptor Antagonist Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global NMDA Receptor Antagonist Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global NMDA Receptor Antagonist Manufacturers, Product Type & Application
  7. 3.7 Global NMDA Receptor Antagonist Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global NMDA Receptor Antagonist Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 NMDA Receptor Antagonist Players Market Share by Revenue in 2025
  11. 3.8.3 2025 NMDA Receptor Antagonist Tier 1, Tier 2, and Tier 3
4 NMDA Receptor Antagonist Market by Type
  1. 4.1 NMDA Receptor Antagonist Type Introduction
  2. 4.1.1 Vaccine
  3. 4.1.2 Monoclonal Antibody
  4. 4.2 Global NMDA Receptor Antagonist Sales by Type
  5. 4.2.1 Global NMDA Receptor Antagonist Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global NMDA Receptor Antagonist Sales by Type (2021-2032)
  7. 4.2.3 Global NMDA Receptor Antagonist Sales Market Share by Type (2021-2032)
  8. 4.3 Global NMDA Receptor Antagonist Revenue by Type
  9. 4.3.1 Global NMDA Receptor Antagonist Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global NMDA Receptor Antagonist Revenue by Type (2021-2032)
  11. 4.3.3 Global NMDA Receptor Antagonist Revenue Market Share by Type (2021-2032)
5 NMDA Receptor Antagonist Market by Application
  1. 5.1 NMDA Receptor Antagonist Application Introduction
  2. 5.1.1 Parkinson's Disease
  3. 5.1.2 Alzheimer's Disease
  4. 5.1.3 Others
  5. 5.2 Global NMDA Receptor Antagonist Sales by Application
  6. 5.2.1 Global NMDA Receptor Antagonist Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global NMDA Receptor Antagonist Sales by Application (2021-2032)
  8. 5.2.3 Global NMDA Receptor Antagonist Sales Market Share by Application (2021-2032)
  9. 5.3 Global NMDA Receptor Antagonist Revenue by Application
  10. 5.3.1 Global NMDA Receptor Antagonist Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global NMDA Receptor Antagonist Revenue by Application (2021-2032)
  12. 5.3.3 Global NMDA Receptor Antagonist Revenue Market Share by Application (2021-2032)
6 Global NMDA Receptor Antagonist Sales by Region
  1. 6.1 Global NMDA Receptor Antagonist Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global NMDA Receptor Antagonist Sales by Region (2021-2032)
  3. 6.2.1 Global NMDA Receptor Antagonist Sales by Region (2021-2026)
  4. 6.2.2 Global NMDA Receptor Antagonist Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America NMDA Receptor Antagonist Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America NMDA Receptor Antagonist Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe NMDA Receptor Antagonist Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe NMDA Receptor Antagonist Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific NMDA Receptor Antagonist Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific NMDA Receptor Antagonist Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa NMDA Receptor Antagonist Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa NMDA Receptor Antagonist Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global NMDA Receptor Antagonist Revenue by Region
  1. 7.1 Global NMDA Receptor Antagonist Revenue by Region
  2. 7.1.1 Global NMDA Receptor Antagonist Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global NMDA Receptor Antagonist Revenue by Region (2021-2026)
  4. 7.1.3 Global NMDA Receptor Antagonist Revenue by Region (2027-2032)
  5. 7.1.4 Global NMDA Receptor Antagonist Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America NMDA Receptor Antagonist Revenue (2021-2032)
  8. 7.2.2 North America NMDA Receptor Antagonist Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe NMDA Receptor Antagonist Revenue (2021-2032)
  11. 7.3.2 Europe NMDA Receptor Antagonist Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific NMDA Receptor Antagonist Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific NMDA Receptor Antagonist Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa NMDA Receptor Antagonist Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa NMDA Receptor Antagonist Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Algernon Pharmaceuticals
  2. 8.1.1 Algernon Pharmaceuticals Company Information
  3. 8.1.2 Algernon Pharmaceuticals Business Overview
  4. 8.1.3 Algernon Pharmaceuticals NMDA Receptor Antagonist Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Algernon Pharmaceuticals NMDA Receptor Antagonist Product Portfolio
  6. 8.1.5 Algernon Pharmaceuticals Recent Developments
  7. 8.2 ATAI Life Sciences
  8. 8.2.1 ATAI Life Sciences Company Information
  9. 8.2.2 ATAI Life Sciences Business Overview
  10. 8.2.3 ATAI Life Sciences NMDA Receptor Antagonist Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 ATAI Life Sciences NMDA Receptor Antagonist Product Portfolio
  12. 8.2.5 ATAI Life Sciences Recent Developments
  13. 8.3 Avanir Pharmaceuticals
  14. 8.3.1 Avanir Pharmaceuticals Company Information
  15. 8.3.2 Avanir Pharmaceuticals Business Overview
  16. 8.3.3 Avanir Pharmaceuticals NMDA Receptor Antagonist Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Avanir Pharmaceuticals NMDA Receptor Antagonist Product Portfolio
  18. 8.3.5 Avanir Pharmaceuticals Recent Developments
  19. 8.4 Axsome Therapeutics
  20. 8.4.1 Axsome Therapeutics Company Information
  21. 8.4.2 Axsome Therapeutics Business Overview
  22. 8.4.3 Axsome Therapeutics NMDA Receptor Antagonist Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Axsome Therapeutics NMDA Receptor Antagonist Product Portfolio
  24. 8.4.5 Axsome Therapeutics Recent Developments
  25. 8.5 Bexson Biomedical
  26. 8.5.1 Bexson Biomedical Company Information
  27. 8.5.2 Bexson Biomedical Business Overview
  28. 8.5.3 Bexson Biomedical NMDA Receptor Antagonist Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Bexson Biomedical NMDA Receptor Antagonist Product Portfolio
  30. 8.5.5 Bexson Biomedical Recent Developments
  31. 8.6 Cessatech
  32. 8.6.1 Cessatech Company Information
  33. 8.6.2 Cessatech Business Overview
  34. 8.6.3 Cessatech NMDA Receptor Antagonist Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Cessatech NMDA Receptor Antagonist Product Portfolio
  36. 8.6.5 Cessatech Recent Developments
  37. 8.7 DemeRx
  38. 8.7.1 DemeRx Company Information
  39. 8.7.2 DemeRx Business Overview
  40. 8.7.3 DemeRx NMDA Receptor Antagonist Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 DemeRx NMDA Receptor Antagonist Product Portfolio
  42. 8.7.5 DemeRx Recent Developments
  43. 8.8 PharmaTher
  44. 8.8.1 PharmaTher Company Information
  45. 8.8.2 PharmaTher Business Overview
  46. 8.8.3 PharmaTher NMDA Receptor Antagonist Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 PharmaTher NMDA Receptor Antagonist Product Portfolio
  48. 8.8.5 PharmaTher Recent Developments
  49. 8.9 Relmada Therapeutics
  50. 8.9.1 Relmada Therapeutics Company Information
  51. 8.9.2 Relmada Therapeutics Business Overview
  52. 8.9.3 Relmada Therapeutics NMDA Receptor Antagonist Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Relmada Therapeutics NMDA Receptor Antagonist Product Portfolio
  54. 8.9.5 Relmada Therapeutics Recent Developments
  55. 8.10 Seelos Therapeutics
  56. 8.10.1 Seelos Therapeutics Company Information
  57. 8.10.2 Seelos Therapeutics Business Overview
  58. 8.10.3 Seelos Therapeutics NMDA Receptor Antagonist Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Seelos Therapeutics NMDA Receptor Antagonist Product Portfolio
  60. 8.10.5 Seelos Therapeutics Recent Developments
  61. 8.11 Small Pharma
  62. 8.11.1 Small Pharma Company Information
  63. 8.11.2 Small Pharma Business Overview
  64. 8.11.3 Small Pharma NMDA Receptor Antagonist Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Small Pharma NMDA Receptor Antagonist Product Portfolio
  66. 8.11.5 Small Pharma Recent Developments
  67. 8.12 UCB
  68. 8.12.1 UCB Company Information
  69. 8.12.2 UCB Business Overview
  70. 8.12.3 UCB NMDA Receptor Antagonist Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 UCB NMDA Receptor Antagonist Product Portfolio
  72. 8.12.5 UCB Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 NMDA Receptor Antagonist Value Chain Analysis
  2. 9.1.1 NMDA Receptor Antagonist Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 NMDA Receptor Antagonist Production Mode & Process
  6. 9.2 NMDA Receptor Antagonist Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 NMDA Receptor Antagonist Distributors
  9. 9.2.3 NMDA Receptor Antagonist Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst